Note: This Guidance is no longer in effect and is for historical purposes only.
Given the sustained increase in variants resistant to bamlanivimab alone, and availability of alternative authorized anti-SARS-CoV-2 monoclonal antibodies, use of bamlanivimab monotherapy is no longer authorized. In March 2021, the California Department of Public Health (CDPH) stopped recommending bamlanivimab monotherapy, and on April 16, 2021, the Food and Drug Administration (FDA) revoked the Emergency Use Authorization (EUA) for bamlanivimab monotherapy.
The currently available anti-SARS-CoV-2 monoclonal antibodies that have received an EUA from the FDA include:
All three products cover current variants circulating in California.
Originally published on December 1, 2021